297 related articles for article (PubMed ID: 34769210)
1. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L.
Costanzi E; Kuzikov M; Esposito F; Albani S; Demitri N; Giabbai B; Camasta M; Tramontano E; Rossetti G; Zaliani A; Storici P
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769210
[TBL] [Abstract][Full Text] [Related]
2. Natural Products-Based Drug Design against SARS-CoV-2 Mpro 3CLpro.
Silva RC; Freitas HF; Campos JM; Kimani NM; Silva CHTP; Borges RS; Pita SSR; Santos CBR
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769170
[TBL] [Abstract][Full Text] [Related]
3. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
4. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K
Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 M
Citarella A; Scala A; Piperno A; Micale N
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
[TBL] [Abstract][Full Text] [Related]
6. Deciphering inhibitory activity of marine algae Ecklonia cava phlorotannins against SARS CoV-2 main protease: A coupled in-silico docking and molecular dynamics simulation study.
Chakraborty A; Ghosh R; Barik S; Mohapatra SS; Biswas A; Chowdhuri S
Gene; 2024 Oct; 926():148620. PubMed ID: 38821329
[TBL] [Abstract][Full Text] [Related]
7. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
8. Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective.
Chakraborty A; Ghosh R; Soumya Mohapatra S; Barik S; Biswas A; Chowdhuri S
Gene; 2024 Sep; 922():148553. PubMed ID: 38734190
[TBL] [Abstract][Full Text] [Related]
9. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
Mody V; Ho J; Wills S; Mawri A; Lawson L; Ebert MCCJC; Fortin GM; Rayalam S; Taval S
Commun Biol; 2021 Jan; 4(1):93. PubMed ID: 33473151
[TBL] [Abstract][Full Text] [Related]
10. Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: Molecular docking and ab initio fragment molecular orbital calculations.
Shaji D; Yamamoto S; Saito R; Suzuki R; Nakamura S; Kurita N
Biophys Chem; 2021 Aug; 275():106608. PubMed ID: 33962341
[TBL] [Abstract][Full Text] [Related]
11. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
12. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
[TBL] [Abstract][Full Text] [Related]
13. Depicting the inhibitory potential of polyphenols from
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
[TBL] [Abstract][Full Text] [Related]
14. Docking Paradigm in Drug Design.
Sulimov VB; Kutov DC; Taschilova AS; Ilin IS; Tyrtyshnikov EE; Sulimov AV
Curr Top Med Chem; 2021; 21(6):507-546. PubMed ID: 33292135
[TBL] [Abstract][Full Text] [Related]
15. Biflavonoids from
Lokhande K; Nawani N; K Venkateswara S; Pawar S
J Biomol Struct Dyn; 2022 Jul; 40(10):4376-4388. PubMed ID: 33300454
[TBL] [Abstract][Full Text] [Related]
16. Fragment-based in silico design of SARS-CoV-2 main protease inhibitors.
Ahmad S; Usman Mirza M; Yean Kee L; Nazir M; Abdul Rahman N; Trant JF; Abdullah I
Chem Biol Drug Des; 2021 Oct; 98(4):604-619. PubMed ID: 34148292
[TBL] [Abstract][Full Text] [Related]
17. Insight into crystal structures and identification of potential styrylthieno[2,3-
El Bakri Y; Ahmad B; Saravanan K; Ahmad I; Bakhite EA; Younis O; Al-Waleedy SAH; Ibrahim OF; Nafady A; Mague JT; Mohamed SK
J Biomol Struct Dyn; 2024 May; 42(8):4325-4343. PubMed ID: 37318002
[TBL] [Abstract][Full Text] [Related]
18. An Updated Review on SARS-CoV-2 Main Proteinase (M
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(6):442-460. PubMed ID: 33292134
[TBL] [Abstract][Full Text] [Related]
19. Proton-Coupled Conformational Activation of SARS Coronavirus Main Proteases and Opportunity for Designing Small-Molecule Broad-Spectrum Targeted Covalent Inhibitors.
Verma N; Henderson JA; Shen J
J Am Chem Soc; 2020 Dec; 142(52):21883-21890. PubMed ID: 33320670
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]